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a b s t r a c t
Rheologically structured vehicle (RSV) gels were developed as delivery systems for vaginal mucosal
vaccination with an HIV-1 envelope glycoprotein (CN54gp140). RSVs comprised a mucoadhesive matrix-
forming and vaginal ﬂuid absorbing polymer. The mucoadhesive and rheological properties of the RSVs
were evaluated in vitro, and the distribution, antigenicity and release of CN54gp140 were analysed byeywords:
aginal delivery
ELISA. CN54gp140 was uniformly distributed within the RSVs and continuously released in vitro in an
antigenically intact form over 24h. Vaginal administration to rabbits induced speciﬁc serum IgG, and IgG
and IgA in genital tract secretions. The RSVs are a viable delivery modality for vaginal immunization.ucosal vaccination
IV-1
. Introduction
The world is currently in the midst of a global HIV/AIDS pan-
emic. UNAIDS estimates 33 million people are currently living
ith HIV/AIDS with 2.7 million newly acquired infections in 2007
lone [1]. The pandemic is fuelled predominantly by heterosexual
ransmission of the virus [2], and the last decade has been char-
cterised by a disproportionate HIV-1 infection burden in women
3]. Globally, almost half of all HIV infected individuals are women
ho have acquired the virus by heterosexual exposure [4–6].
It is broadly acknowledged that the ultimate prophylactic
trategy for HIV/AIDS would be the development of an efﬁca-
ious vaccine. However, the mechanisms by which HIV-1 evades
ntibody-mediated neutralisation have hindered the development
f a potent vaccine [7,8]. Over two decades into the HIV pandemic
nd a vaccine remains as elusive as ever. The pandemic contin-
es to outpace global effort at prevention and control [9]. In the
bsenceof aneffectivevaccine strategy,HIVpreventionhasevolved
obe a verymultilateral termencompassing structural, behavioural
nd the biomedical preventive strategies, that now include vagi-
al microbicides, oral pre-exposure prophylaxis, implementation
f male circumcision, highly active antiretroviral therapy, and of
ourse vaccine development [10–13].
∗ Corresponding author. Tel.: +44 028 90972296; fax: +44 028 90247794.
E-mail address: rhonda.curran@qub.ac.uk (R.M. Curran).
264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2009.08.088© 2009 Elsevier Ltd. All rights reserved.
As such, there remains a profound scientiﬁc rationale to pursue
and emphasise the development of female-controlled preven-
tive strategies, principally involving the cervix and vagina as the
predominant mucosal viral portal of entry in heterosexual trans-
mission,with a view to eliciting sterilising immunity at the primary
point of viral entry. Such a vaginal vaccine should be inexpensive,
safe, stable, easy to store and should induce long-lasting high-
titre protectivemucosal and systemic immune responses to diverse
viral isolates through repeated and/or sustained female-controlled
administration.
In the case of HIV-1 the envelope spike is the only viral target
available for neutralising antibodies [14]. As a result, themajority of
candidate HIV-1 vaccines have involved viral surface envelope gly-
coproteins. The therapeutic efﬁcacy of proteins as pharmaceuticals
depends largely on maintaining intended biological activity, and
in the case of protein vaccines maintaining intended antigenicity.
Vaginal vaccination approaches are well documented in the liter-
ature; most involve the administration of antigen in simple buffer
solutions rather than delivery modalities speciﬁcally designed for
vaginal administration [15–19].
From a formulation perspective, inducing effective antigen-
speciﬁc immune responses by cervicovaginal instillation of buffer
solution containing solubilised antigen is far from ideal owing to
the potential for leakage at the administration site, rapid enzymatic
degradation of the antigen, the inﬂuence of the menstrual cycle,
and inadequate exposure of antigen to themucosal associated lym-
phoid tissue. It is considered that administration of simple antigen
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olutions is unlikely to promote the prolonged mucosal contact
equired for effective uptake of antigen and immunogenicity at the
aginal mucosal epithelium.
A limited number of alternative approaches for vaginal admin-
stration of antigens have been reported, including antigen-soaked
ampons [20]or suppositories [21].However, there is a strong ratio-
ale for expanding the formulation options for effective vaginal
dministration of vaccine candidates. As a result, the true potential
f protein pharmaceuticals as vaccines for intravaginal administra-
ion is and will be dependent on advances in formulation science
hat will promote effective stability, delivery, protection and pro-
onged exposure of antigen to target cells. Potentially, this may be
chieved through sustained-release semi-solid polymeric delivery
latforms. To date, the relative success of sustained-release poly-
eric based protein delivery systems has largely been constrained
o low-molecular weight peptides [22]. However, semi-solid poly-
eric delivery platforms, such as thermosensitive in situ gelling
ucoadhesive systems developed for the sustained vaginal deliv-
ry of large molecular weight recombinant hepatitis B surface
ntigen (HBsAg) [23] and human papillomavirus 16 L1 virus-like
articles (HPV 16 L1 VLP) [24], are continuously being developed
o effectively deliver biomacromolecules and have been shown
o enhance vaginal immunization. Such innovative approaches
re required for the vaginal delivery of relatively large molecular
eight HIV-1 envelope proteins.
In this manuscript we describe the development and char-
cterisation of an innovative gel delivery method for vaginal
ucosal vaccination with an HIV-1 vaccine candidate, a clade-C
ecombinant trimeric envelope glycoprotein (CN54gp140). Vaginal
dministration of these polymeric, highly viscous, mucoadhesive,
etentive, gels (so-called rheologically structured vehicles, RSVs)
as evaluated in a rabbit model. The RSV gels in this study con-
ain multiple polymer components, including a mucoadhesive and
ydrophilic matrix-forming polymer and a polymeric component
apable of absorbing vaginal ﬂuid and potentially offering addi-
ional retention advantages.
. Materials and methods
.1. Materials
Hydroxyethylcellulose (HEC/Natrosol 250-HHX-Pharm),
ydroxyethylcellulose (HEC/Natrosol 250-HX-Pharm) and
olycarbophil (Noveon AA1) were kindly donated by Aqualon
Warrington, UK) and Noveon Pharma GmbH & Co KG (Raubling,
ermany). (Poly)vinylpyrollidone (Plasdone K-90) was kindly
onated by International Speciality Products (Ohio, USA). Galan-
hus nivalis (GNA) was obtained from Vector Laboratories
Peterborough, England). 3,3′,5,5′-Tetramethylbenzidine perox-
dase substrate (TMB/E) was obtained from Millipore U.K. Ltd.
Watford, England). The HIV-1 gp41 speciﬁc monoclonal antibody
F3 utilized for ELISA was obtained from Polymun Scientiﬁc
Vienna, Austria). GMP manufactured Carbopol® 974P gel, formu-
ation #2449 was kindly donated by Particle Sciences (Bethlehem,
A, USA). All other chemicals were purchased from Sigma–Aldrich
Poole, Dorset, UK) and were of AnalaR, or equivalent quality.
eactibind 96 well microplates were obtained from Perbio Science
Northumberland, England).
The recombinant trimeric envelope glycoprotein CN54gp140
as supplied by S. Jeffs (Imperial College, London). CN54gp140
as encoded by the CN54gp140REKR HIV-1 envelope gene cas-
ette derived from the clade-C/B’ HIV-1 molecular clone p97CN54
f Chinese origin developed by Wolf and Wagner, University of
egensburg, Germany [25]. The protein was expressed in CHO
ells following removal of the membrane-spanning and intracy-27 (2009) 6791–6798
toplasmic domains of gp41. CN54gp140 was also manufactured
to GMP speciﬁcation and supplied by Polymun Scientiﬁc (Vienna,
Austria).
2.2. Preparation of gel formulations
The RSV gel formulations were hand-mixed in a step-wise fash-
ion following thorough mixing under vacuum using the HiVacTM
Bowl bone cement mixing system (Summit Medical Limited,
Gloucestershire, UK). A 3% (w/w) Noveon AA1 gel with 0.1% (w/w)
sorbic acid in sterile water was prepared and pH adjusted to pH 6
using sodiumhydroxide.HEC/Natrosol 250-HHX-Pharmwasadded
at 3% (3% RSV) or 5% (5% RSV) (w/w) and Plasdone K-90 was
added at 4% (w/w). The RSV gel formulations for the in vitro stud-
ies were centrifuged for two periods of 30min at 3000 rpm (Jouan
C312).
HEC gel was prepared based on the recipe of the “Universal
Placebo” gel [26] and was prepared by dissolving 1.1% benzyl alco-
hol, 0.85% sodium chloride, 0.01% sodium hydroxide in 95.16%
(w/w)deionisedwater; followedby slowlydissolving2.7%Natrosol
250-HX-Pharm using an overhead motorized stirrer with a pro-
peller blade (Heidolph, Schwabach, Germany). The ﬁnal pH was
determined and adjusted if necessary to pH 7.
2.3. Measurement of the force required to expel the RSV gel
formulations from a syringe
“Syringeability” was determined by measuring the work
required to expel the RSV gel formulations from a syringe, using
the texture analyser (Stable Micro Systems) with texture pro-
ﬁle analysis probe (TPA) in compression mode. To measure the
ease of delivery of the RSV gels, 3 g was packed into a modiﬁed
syringe (tip and base removed), whilst minimising the introduc-
tion of air. The syringe was then vertically clamped and the TPA
probe was lowered until initial contact with the syringe plunger
was observed. The probe was lowered at a rate of 2.0mm/s
through a distance of 30mm and the resistance to expression of
the syringe contents (work done) was determined from the area
under the force–time plot recorded during compression of the
plunger.
2.4. Evaluation of the mucoadhesive strength of the RSV gel
formulations
Mucoadhesive strength was determined using the texture anal-
yser in tension mode, to measure the force required to detach a
mucin disc from the surface of the RSV gels. Porcine mucin discs
(250mg) were prepared by compression in a Carver press (13mm
diameter die) for 30 susing adeﬁned compression force (10 tonnes)
and horizontally attached to the bottom end of a TPA probe using
sticky ﬁxers. Immediately prior to mucoadhesive testing, the disc
was hydrated by immersion in a 5% mucin solution for 30 s. RSV
gel samples packed into shallow cylindrical vessels were placed
under the probe which was lowered until the attached hydrated
mucin disc contacted the RSV gel surface. A force of 1N was then
applied for 30 s ensuring intimate contact between the disc and the
RSV gel. The force required to detach the mucin disc from the sam-
ple was then determined by moving the probe upward at a rate of
1.0mm/sand isdeﬁnedas thepeakvalueof the resultant force-time
plot.2.5. Rheological analysis of RSV gel formulations
Rheological properties can to an extent deﬁne the predicted
behaviour of a material in vivo. Oscillatory data permits interpre-
tation of how the RSVs will behave under low stresses or strain,
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ow their characteristic will effect the release properties and pas-
ive seepage over epithelial tissues. Comparison of structural data
btained from rheological evaluation of the RSVs in this study
ay provide useful information for the prediction of clinical per-
ormance. Oscillatory rheological analyses were performed using
n AR2000 rheometer (T.A. Instruments, Surrey, England) at 25 ◦C
ith a 2 cm diameter parallel plate geometry and a plate gap of
000m. Samples were applied to the upper plate using a spat-
la to avoid shearing and were applied to the Plate 5min before
nalysis to allow for the relaxation of stresses introduced during
ransferral. Analyses were performed in at least triplicate over a
requency range from 0.1 to 10Hz. The linear viscoelastic region
LVR) was investigated by increasing oscillatory stress (torque
weep between 1 and 30Pa) at a ﬁxed frequency (0.1 and 10Hz)
nd was identiﬁed as the region where the stress and strain were
irectly proportional and the storage modulus (G′) remained con-
tant. Calculation of G′, loss modulus (G′ ′) and dynamic viscosity
ere performed using proprietary software.
.6. Point-of-use syringe mixing
Two 5ml syringes were attached via a 1.5 cm length of
olypropylene tubing with an internal diameter of 3mm. A solu-
ion of a model water-soluble compound (erioglaucine) or of
N54gp140 was added to an aliquot of 5% RSV or 3% RSV respec-
ively, in the samebarrel of oneof the5ml syringes to aﬁnal volume
f 3g. Erioglaucine or CN54gp140 andRSVwere combined together
y 40 passes from one syringe to another via the polypropylene
ubing.
The point-of-use syringe mixing method was validated with
rioglaucine to preserve stock CN54gp140. Five aliquots of eri-
glaucine loaded syringe mixed 5% RSV (expected concentration
5.8g/0.25g 5% RSV) were diluted overnight in 100ml deionised
ater in an orbital incubated shaker at 37 ◦C. The concentration of
rioglaucine was analysed by UV spectrophotometry (630nm).
.7. Construction of CN54gp140 spiked RSV gel calibration curves
or ELISA
Two calibration curve formats were trialled for construction of
“CN54gp140-spiked 3% RSV” calibration curve that could correct
or potential matrix effects and loss of detectable CN54gp140 post-
ormulation and overnight sample preparation. Format 1 involved
he individual preparation of each point of the calibration curve by
oading 3% RSV gels with different CN54gp140 concentrations and
iluting overnight in 0.01M phosphate buffer (pH 7.4) containing
.05% Tween-20 and 0.14M NaCl (PBST) in an orbital incubated
haker (Infors HT) at 37 ◦C and 60 rpm. Format 2 involved the
reparation of a CN54gp140 loaded 3% RSV gel as the top point
f the calibration and a blank 3% RSV gel which was used follow-
ng overnight incubation in PBST to dilute the CN54gp140 loaded
SV gel for construction of the calibration curve. The lower lim-
ts of detection (LOD) were calculated using 3 SD of each blank
ample.
.8. ELISA for the detection/quantiﬁcation of CN54gp140
A heterogeneous indirect sandwich ELISA was optimised for
ntended end-use, to detect andquantify CN54gp140 indilutedRSV
els. Wells were incubated with 50l/well of GNA at 10g/ml in
eionised water overnight at 37 ◦C. The wells were washed (wash
rocedure was 5 washes in PBST) and blocked for 1h at ambi-
nt temperature with PBST-serum (PBST with 5% sterile-ﬁltered
orcine serum). Standards, samples and controls were diluted in
BST-serum and incubated for 2h at ambient temperature. The
ells were washed and incubated with 50l/well HuMab 5F3 for7 (2009) 6791–6798 6793
1h at ambient temperature. The wells were washed and bound
antibody was detected using goat anti-human immunoglobulin
(IgG) peroxidase conjugate diluted 1:5K in PBST-serum and incu-
bated for 1h at ambient temperature. Afterwashing, thewellswere
incubated with 100l TMB/E. The reaction was terminated by the
addition of 50l of 2.5MH2SO4. The correctedmeanof the quadru-
ple absorbance (A450) measurements of each sample was obtained
and compared with those of the negative controls.
2.9. Uniformity of mixing
Uniformity of mixing of formulating CN54gp140 within the 3%
RSV by the syringe mixing procedure was analysed using the ELISA
method. Five single dose 3% RSVs containing CN54gp140 (106g
per 3g gel) were prepared using the syringe mixing procedure.
0.5 g aliquots of the single dose 3% RSVs were weighed into 100ml
sterile screw-cap polypropylene containers and diluted in 100ml
PBST overnight in an orbital incubator at 37 ◦C and 60 rpm. The
concentration of CN54gp140 in each aliquot was determined by
ELISA.
2.10. In vitro CN54gp140 release studies
2.10.1. Cap method
Five single dose 3% RSV formulations were prepared to a
CN54gp140 loading of 100g per 3g 3% RSV and transferred to
the inside of a McCartney vial cap. The McCartney vial caps were
ﬁxed to the bottom of 100ml sterile screw-cap polypropylene con-
tainers using vacuum grease. The McCartney vial caps containing
CN54gp140 loaded 3% RSV gel were immersed in 30ml PBST and
maintained at 37 ◦C and stirred at 60 rpm in an orbital incubator.
At designated time intervals 3ml of release media was removed
for analysis and replaced with 3ml of fresh PBST. When it was
necessary release samples were stored at 4 ◦C before analysis by
ELISA.
2.10.2. Expulsion method
The expulsion release method was as per the cap method with
the exception that CN54gp140 loaded gels (100g/3 g 3% RSV;
98g/3 gHEC; 98g/3 gCarbopol®)were expulsed into the release
media as opposed to being contained within McCartney vial caps.
2.11. Assessment of the stability of CN54gp140 formulated within
the RSV gel
Three single dose 3% RSVs containing CN54gp140 (106g per
3g gel) were prepared using the syringe mixing procedure. The
recovery of CN54gp140 from 0.5 g aliquots of the single dose 3%
RSVs stored at three different temperatures (4 ◦C, ambient, 37 ◦C)
was monitored over time. Following remixing of the CN54gp140
loaded3%RSVgel at each timepoint the aliquotswereweighed into
100ml sterile screw-cap polypropylene containers and diluted in
100ml PBST overnight in an orbital incubator at 37 ◦C and 60 rpm.
The concentration of CN54gp140 in each aliquot was determined
by ELISA.
2.12. Immunogenicity/toxicology-irritancy study
2.12.1. In vivo procedures
12 female 10–12-week-old New Zealand white rabbits were
each given 9 intravaginal immunizations of 65g of CN54gp140
in either of two RSV gel formulations: 3% RSV or 5% RSV, at a
total volume of 400l administered at days 1, 3, 5, 8, 10, 12,
15, 17 and 19. Just prior to administration, antigen and gel were
mixed according to the point-of-use syringe mixing method. Air
was removed fromeach syringeby centrifugation at 400× g and the
6 ccine
h
a
d
a
i
d
s
X
t
y
v
o
f
c
I
b
u
i
t
A
b
a
B
m
i
a
i
R
i
w
(
c
a
2
E
c
(
b
3
a
w
d
d
i
T
s
d
w
d
a
a
(
h
a
f
G
I
s
a
t
1
g794 R.M. Curran et al. / Va
omogenousmixturewas transferred to1ml syringes for dosing, to
llow for accurate administration. The gel formulationswere intro-
uced approximately 6 cm into the vagina via a soft rubber catheter
ttached to the syringe. Blood samples for serological, haematolog-
cal and blood chemistry analysis were taken pre-treatment and on
ays6, 13 and20. Secretions fromthevagina and thevestibulewere
ampledusing ophthalmic sponges (Weck-CelTM spears,Medtronic
omed, Inc.) post mortem from tissues that had been removed for
his speciﬁc purpose (so as not to interfere with histological anal-
sis). A sterile spear was placed on the mucosal surface of the
agina for 2min to absorb any secretion. A second spearwas placed
n the mucosal surface of the vestibule. Secretions were eluted
rom the sponges by placing each spear into a spin-X tube (Costar)
ontaining 300l extraction buffer (protease inhibitor cocktail set
, Calbiochem, EMD Biosciences). Samples were frozen at −80 ◦C
efore dispatch to the laboratory. Standardised procedures were
sed for the assessment of any toxicological or irritancy effects
ncluding visual inspection at least twice daily for evidence of reac-
ion to treatment or ill health and weekly physical examination.
nimals were observed for signs of vulval irritation, discharge or
leeding from the vagina before each intravaginal administration
nd any indications were graded on a standardised irritancy scale.
ody weights were recorded one week before study commence-
ent and regularly then at the ﬁrst and following each subsequent
ntravaginal inoculation. Animals were killed humanely at day 20
nd detailed macroscopic and histological analysis undertaken. All
n vivo and necropsy procedures were carried out by a Contract
esearchOrganisationonbehalf of the sponsors, aspart of apreclin-
cal evaluation for Phase I testing in humans. All in vivo procedures
ere carried out in compliance with the United Kingdom Animals
Scientiﬁc Procedures) Act 1986 and animals were maintained in
ompliance with the associated Codes of Practice for the Housing
nd Care of Animals.
.12.2. Assay of antibody responses
IgG binding antibodies were measured using a standardised
LISA. 96-well plates (Greiner Bio-One medium binding) were
oated with CN54gp140 at 5g/ml in phosphate buffered saline
PBS) for 1h at 37 ◦C. Plates were washed 4 times in PBST before
locking with PBST containing 10% foetal bovine serum for 1h at
7 ◦C. After further washing, sera diluted in PBST or mucosal elu-
tes were added and incubated for 1h at 37 ◦C. Bound antibody
as detected with monoclonal anti-rabbit IgG (-speciﬁc) peroxi-
ase conjugate (Sigma A1949) diluted to optimal concentration as
etermined by checkerboard titration. After incubation and wash-
ng as above, colour was developed by addition of TMB (Sureblue
MB 1-component peroxidase substrate (KPL)). The reaction was
topped with TMB Stop Solution (KPL) after 5min incubation in the
ark and the plates were read immediately at 450nm.
For the detection of IgA antibody a modiﬁed ELISA protocol
as used that had previously been optimised for sensitivity and
iscrimination of positive and negative control samples, based on
human immunoglobulin ELISA. Bound IgA was detected by the
ddition of biotin conjugated to goat anti-rabbit IgA (-speciﬁc)
Autogenbioclear ABN116B) followed by avidin conjugated to
orseradish peroxidase (Sigma A7419). The substrate reaction was
llowed to proceed for 10min for the IgA ELISA. Standard curves
or IgG detection were derived using rabbit antiserum to HIV-1
B8 gp120 (Programme EVA, Centre for AIDS Reagents, National
nstitute for Biological Standards and Control, ARP440.1/R546). A
peciﬁc IgA antibody containing rabbit serum was not available. All
ssays used normal rabbit serum (Sigma, R9133) as a negative con-
rol. For initial screening, serum sampleswere tested in triplicate at
:100 and mucosal samples were tested undiluted. An absorbance
reater than or equal to 0.2 was used as the positive cut-off.27 (2009) 6791–6798
3. Results
3.1. Rheological analysis, mucoadhesive strength and
syringeability
The 3% RSV gel formulation was compared to the 5% RSV gel for-
mulation. The change in rheological viscoelastic properties (G′, G′′,
and ′ at 5 representative frequencies) and mechanical properties
associated with the inclusion of different percentages of HEC were
determined by oscillatory rheology and TPA respectively (Table 1).
5% RSV was more rheologically structured than 3% RSV display-
ing higher values of G′, G′′ and ′ (across the entire frequency range
studied), parameters which signify how elastic, liquid and viscous
a material is. The values of G′ and G′′ increased as a function of
frequency. Physically entanglednetworks characteristicallydisplay
increases in G′ and G′′ with increasing oscillatory frequency, how-
ever the increases observed here were relatively small suggesting
a high degree of physical interaction between the polymeric com-
ponents [27].
The lower values of ′ observed with the 3% RSV would suggest
that this lower viscosity formulation may be more easily applied
than the 5% RSV formulation, using a vaginal gel applicator, and
in turn may more readily coat the epithelial surfaces. The lower
hardness and compressability values obtained during TPA studies
and the lower amount of work required to expel the formulation
in syringeablility studies (employing a device resembling that typ-
ically used as a vaginal gel applicator) in comparison to 5% RSV
corroborate this. Despite ease of administration, higher levels of
mucoadhesiveness were maintained and are likely to ensure pro-
longed adhesion of the formulation to the mucosal surfaces.
3.2. Validation of the syringe mixing method
Assuming homogeneous distribution of erioglaucine post-
syringe mixing, a 0.25g aliquot of 5% RSV had an expected
erioglaucine loading of 15.8g. Theoretical concentration of dis-
persed erioglaucine aliquots was 158ng/ml. The mean actual
concentration as determined by UV spectrophotometry was
147.9±6.2ng/ml (RSD 4.2) indicating homogeneous distribution
of erioglaucine throughout the 5% RSV.
3.3. ELISA for the detection/quantiﬁcation of CN54gp140
Nodifferencewas observed between Format 1 and2 for the con-
structionofCN54gp140-spiked3%RSVcalibrationcurves, therefore
format 2 was selected to ensure minimal use of CN54gp140. A
linear calibration plot for CN54gp140 in PBST was observed over
the range 0.003–0.05g/ml (R2 0.9988) and for the CN54gp140-
spiked 3% RSV curve over the range 0.01–0.7g/ml (R2 0.9968)
(Fig. 1). The LOD of CN54gp140 in PBST was 0.003g/ml and the
RSD over the entire linear range of the assay of was <8.1%. The LOD
ofCN54gp140-spiked3%RSVwas0.01g/ml and theRSDwas<66%
until 0.04g/ml (4LOD) and <11% thereafter. The A450 values of
the linear range of CN54gp140 in PBST assay were on average 92%
higher than those of the CN54gp140-spiked 3% RSV assay. When
required samples were diluted to within the linear range of the
assay. A CN54gp140-spiked 3% RSV curve was applied to the uni-
formity of mixing study and stability study and a CN54gp140 in
PBST curve was applied to the release studies.
3.4. Uniformity of mixingAssuming homogeneous distribution of CN54gp140 post-
syringe mixing, a 0.5 g aliquot of 3% RSV had an expected
CN54gp140 loading of 17.6g. Theoretical concentration of
CN54gp140 in diluted RSV gel was 0.35g/ml. The mean actual
R.M. Curran et al. / Vaccine 27 (2009) 6791–6798 6795
Table 1
Change in rheological viscoelastic properties (G′ , G′′ , and ′ at 5 representative frequencies) and mechanical properties, with increasing HEC concentration within RSV gel
formulations determined by oscillatory rheology and TPA respectively.
Formulation Oscillatory rheology data Texture proﬁle analysis
Freq. (Hz) G′ (Pa) G′′ (Pa) ′ (Pa s) Mucoadhesive
strength (N)
Syringeability (Nmm) Hardness (N) Compressibility (N s)
3% RSV 1.14 3940±285 965±64 134±9 0.467±0.072 42.58±8.90 3.17±0.09 3.18±0.09
3.23 4618±330 1046±71 52±3
5.31 4939±323 1081±69 32±2
7.40 5139±283 1101±59 24±1
10.00 5337±257 1122±45 18±1
5% RSV 1.14 6149±130 1432±33 200±5 0.37±0.04 66.94±9.19 6.28±0.2 6.26±0.11
c
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(Table 2). Serum IgG antibody was detected as early as day 13 in
1 of the animals receiving 3% RSV and in 3 of 6 animals receiving3.23 7126±150 1465±38 72±2
5.31 7578±150 1474±38 44±1
7.40 7853±176 1479±38 32±1
10.00 8075±294 1475±47 23±1
oncentration as determined by ELISA was 0.36±0.02g/ml (RSD
.3).
.5. In vitro release data for CN54gp140
The degree of matrix associated dampening was expected to
ary over the course of the release studies therefore the concen-
rations of CN54gp140 were determined using CN54gp140 in PBST
alibration curves and the data interpreted as minimum release.
he percentage cumulative release proﬁles of CN54gp140 from 3%
SV gels (cap method: RSD 0.15–24.70, expulsion method: RSD
.11–18.42), from HEC gels (RSD 3.72–44.15) and from Carbopol®
els (RSD 0.88–17.85) are shown in Fig. 2. Using the expulsion
ethod 45.66% of CN54gp140 was released within 24h, 8-fold
igher than when using the cap method (5.70%). Using the expul-
ion method 45.7% of CN54gp140 was released from the 3% RSV
el and 57.36% from the HEC gel within 24h, compared to 98.17%
ithin 20min in the case of the Carbopol® gel (Fig. 2).
.6. Stability data
Recovery values of CN54gp140 from 0.5 g aliquots of 3% RSV at
ifferent stability storage temperatureswereas follows: +4 ◦C—92%
ay 2, 92% Day 3 and 81% Day 9; ambient—83% Day 2, 82% Day 3,
4% Day 4, 59% Day 9; 37 ◦C—77% Day 2, 53% Day 3, 42% Day 4, and
1% Day 9.
ig. 1. Calibration curves for the indirect heterogeneous sandwich ELISA of free-
N54gp140 ( CN54gp140-spiked 3% RSV,  CN54gp140 in PBST, n=4).3.7. Vaginal irritation and toxicity
All animals survived to the end of the treatment period and
no signs of systemic toxicity were observed following administra-
tion of the vaccine in either of the gel formulations. There were
no effects on body weight, food consumption or organ weights and
therewereno treatment-relatedﬁndings bymacroscopic examina-
tion. Changes in the vagina determined byhistological examination
were scored using the method of D’Cruz et al. [28] modiﬁed from
that of Eckstein et al. [29]. Overall cumulative scores fell within
the acceptable range for human vaginal irritation potential (0–8)
for all animals. Animals given CN54gp140 in 3% RSV had the low-
est scores, ranging from 1 to 3; whereas, animals receiving antigen
formulated in 5% RSV had scores ranging from 4 to 7.
3.8. Induction of speciﬁc antibody responses
Five of six rabbits receiving CN54gp140 antigen formulated in
3% RSV gel and 5 of 6 animals receiving antigen formulated in 5%
RSV gel had evidence of speciﬁc antibody responses detectable
in serum (Fig. 3) and in secretions from the female genital tract5% RSV with titres ranging from 130 to 320. By day 20, the last
day of the study, IgG antibody titres had increased in all these ani-
Fig. 2. Mean percentage cumulative release versus time proﬁle for CN54gp140 (©
conﬁned 3% RSV, n=5,  expulsed 3% RSV, n=5,  expulsed HEC, n=5,  expulsed
Carbopol® , n=3.
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iig. 3. Intravaginal immunization of rabbits with CN54gp140 formulated in 3% RS
gA () gp-140-speciﬁc ELISA titres were determined by dilution to a standardized
als and another 6 animals had sero-converted, although in two
nimals, one from each group, titres only just reached the mini-
um detectable. Overall, serum IgG antibody titres ranged from
00 to 1500 at day 20. Titres were broadly similar between the two
roups (100–1280 and 100–1500 for each group respectively). IgA
ntibody was undetectable in any serum sample at or above the
inimum titre of 10.
Female genital tract secretions from the two animals that failed
o sero-convert also tested negative for antibody. All other animals,
lbeit sometimes at low titre, had evidence of antibody in vaginal
nd or vestibule secretions. Four animals in each group had IgG
able 2
ntravaginal immunization of rabbits with CN54gp140 formulated in 3% RSV or 5%
SV stimulated production of IgG and IgA gp140-speciﬁc antibodies detected in
aginal and vestibular sponge eluates taken 20 days after the start of immunization.
Animal no. RSV (%) IgG titre (absorbance) IgA titre (absorbance)
Vagina Vestibule Vagina Vestibule
#07 <1 1 <1 <1
#08 <1 3 3 <1
#09 3 <1 <1 <1 +(0.23)
#10 70 55 +(0.5) <1
#11 125 12 +(0.36) <1
#12 <1 <1 <1 <1
#13 <1 <1 <1 <1
#14 650 81 <1 <1
#15 5 50 70 +(0.24) +(0.24)
#16 <1 <1 37 70
#17 7 3 +(0.57) +(0.71)
#18 75 1 +(0.99) +(1.74)
nd-point titres are shown where sufﬁcient volume was available for analysis.
here titration was not possible, + indicates a result above the pre-deﬁned cut-off
n undiluted eluatewith the corresponding absorbance value shown in parentheses.r 5% RSV stimulated production of systemic IgG anti-gp140 antibody. IgG () and
oint and the limits of detection are shown for IgG ( ) and IgA ( ).
speciﬁc antibody detectable in mucosal samples with titres that
were broadly associated with IgG titres in serum. Interestingly, 4
animals in each group also had mucosal IgA antibodies and in two
cases IgA was detectable in the absence of mucosal IgG. Constraints
of volume precluded titration of mucosal samples in most cases;
however, in one animal where IgG antibody was undetectable in
genital tract secretions IgA was present at relatively high titre.
4. Discussion
Due to their low cost, ease of manufacture, and precedence
of use in the topical administration of drugs, conventional semi-
solid gel systems are commonly employed to administer drugs via
the vaginal route, mainly for the treatment of vaginal infection,
contraception, and hormone replacement therapy. More recently,
gel-based formulations are being widely developed for the deliv-
ery of HIV microbicides [30–32]. A small number of studies have
reported the use of gel systems for the vaginal delivery of vaccines
[23,24,33–35]. However, thepoor vaginal retentionof conventional
gel formulations represents a signiﬁcant challenge for those clini-
cal indications where sustained delivery is predicted to potentially
enhance efﬁcacy, such is the case for the vaginal delivery of HIV
vaccines.
The development of protein-based HIV vaccine pharmaceuti-
cals (HIV envelope proteins) is particularly challenging due to the
fragility and complex structure of the protein molecules involved
[36,37], the cervicovaginal administration of which is further sub-
ject to many other constraints such as enzymatic degradation.
Whilst the recombinant envelope protein used in this study has
proven to be exceptionally stable, relative to other HIV-1 recom-
binant envelope glycoproteins, in general formulation strategies
should avoid processes that may have a detrimental effect on the
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nvelope protein in order to preserve stability and subsequent bio-
ogical activity [38].
Prolonged retention and intimate contact of antigen with the
aginal mucosa are achievable through manipulation of the rhe-
logical and mucoadhesive properties of semisolid platforms. We
ave developed RSV gel formulations that are designed to provide
nhanced mucosal retention within the vagina and have the ability
o spread and coat the epithelial surface whilst maintaining rhe-
logical structure even when subject to the effects of ambulation,
eepage between epithelial surfaces, sexual intercourse and dilu-
ion with vaginal ﬂuids. A bioadhesive component was included in
he formulation design to promote intimate contact of the polymer
ith the mucosal surfaces. Although thermoreversible gelling sys-
ems may offer the advantage of ease of vaginal administration, the
SV gels are expected to offer retention advantages on account of
heir dilution-resistant characteristics.
Two RSV gel formulations were used in this study, containing
% and 5% HEC. The lower viscosity version of the formulation,
chieved by reducing thematrix-forming polymer component HEC
rom 5% to 3%, was investigated to facilitate ease of dispensing
nd application in a clinical setting. Rheological analyses demon-
trated that reducing the HEC component reduced the G′ (at a
requency of 1.142Hz) of the RSV gel from 6149±285Pa (5% RSV)
o 3940±285Pa. As predicted, this decrease in rheological struc-
ure correlated with signiﬁcant decrease in the syringeability of
he RSV gel formulation (work done for 3% RSV 42.58±8.9Nmm,
ompared to 5% RSV 66.94±9.19Nmm). For comparative pur-
oses the G′ (at a frequency of 1.142Hz) of three considerably
ess viscous commercial gel preparations were determined by
scillatory rheology: Acijel (1402±156Pa), Metrogel (177±8Pa),
nd Zidoval (642±32Pa). Texture proﬁle analysis also conﬁrmed
ower levels of hardness and compressibility (3.169±0.086N and
.182±0.089Ns respectively (3% RSV) compared to 6.282±0.2N
nd 6.257±0.1095Ns respectively (5% RSV)), with a concomitant
ncrease in mucoadhesive bond strength (0.467±0.072N (3% RSV)
ompared to 0.37±0.041N (5%RSV)). This trendhas been observed
efore [39,40]. Based on these results, the 3% RSV gel formulation
s expected to facilitate ease of vaginal administration compared to
he 5% RSV, but still offer considerable retention compared to other
ore conventional vaginal gel products.
Preliminary evaluation of the point-of-use syringe mixing
ethod was validated using the higher viscosity 5% RSV gel for-
ulation using the model compound erioglaucine. Further studies
onﬁrmed that the same mixing protocol was suitable for ensur-
ng homogeneous distribution of CN54gp140 in the lower viscosity
% RSV gel formulation. All subsequent in vitro studies were per-
ormed with the 3% RSV gel, although both gels were evaluated in
he rabbit studies.
The release study using the expulsion format was considered to
ore closely model in vivo administration (or vaginal smearing).
igh RSDs were anticipated for the expulsion method as the non-
onﬁnednatureof this releasemethod leads tovariable surface area
vailable for dissolutionof CN54gp140 into the surrounding release
edia. In fact, similar variability in release data for both methods
as observed, as measured by RSDs (Fig. 2). The in vitro release
f CN54gp140 from three different gel formulations (3% RSV, HEC
el, and Carbopol® 974P gel) was monitored over a 24h period.
lmost 100% of CN54gp140 was released from the Carbopol® gel
ithin10min. TheHECandRSVgel formulations released inamuch
ore sustained manner. As anticipated, the 3% RSV gel formula-
ion released at the slowest rate. This sustained-release behaviour,
n combination with the site-retentive characteristics predicted
rom the rheological and mucoadhesive data, may render the RSV
el formulation most suitable for use in vaginal immunization. In
articular, although the correlates of HIV-1 protective immunity
emain unknown, we are assuming that persistent local exposure7 (2009) 6791–6798 6797
of the antigen at the mucosal surface is essential for induction of
effective adaptive immunity.
Although the GMP manufactured CN54gp140 has proven to be
exceptionally stable in simple buffer solutions, early indications
suggest that stability is compromised when formulated within the
3% RSV gels. This may have implications for temperature storage
and distribution of a gel-based HIV vaccine.
This study was designed primarily to conﬁrm the effective-
ness of the RSV gel formulations as vaginal delivery modalities for
mucosal vaccination. Using a preliminary animal immunogenicity
study (designed to assess the toxicity or local irritation of the RSV
gel formulations as a preclinical testing requirement) it was deter-
mined that speciﬁc immune responses could be achieved using the
RSV gels as vaginal delivery vehicles for CN54gp140. It was par-
ticularly encouraging that although serum IgA antibodies were not
detected evidence of IgA as well as IgG antibodies was obtained
from the female genital tract secretions. In particular, the detec-
tion of IgA antibodies in secretions suggests that these were of
local origin as serum IgA was not detected in the same animals:
further studies are required to validate this. IgG antibody may also
be generated locally; however the female genital tract is thought
to be relatively permeable to antibody derived from the circulation
[41]. Small volumes of secretions recovered in this study precluded
analysisof antibody titre referenced to total immunoglobulin;how-
ever, in an associated study with the same protein formulated
in Carbopol® gel the proportion of speciﬁc antibody detected in
mucosal secretions was 8.5–9.0-fold higher compared to serum
[42]. The observation of immune response following vaginal vacci-
nation with the RSV gel formulations is encouraging as the vagina
is considered to be a poor inductive site for humoral immunity
[43]. Ongoing studies will provide comparative data in different
species and will assess whether responses to RSV gel formulations
are increased following priming via alternative routes (parenteral
or intranasal).
CN54gp140administered inbothRSVgel formulationsmounted
similar immune responses in both rabbit groups. Although in vitro
release of CN54gp140was not carried out for 5% RSV, itmay be pre-
dicted that the CN54gp140 release rate in vitro may be marginally
faster from 3% RSV compared to 5% RSV. No such assumptions can
be made on the elicitation of immune responses in vivo. Although
the rabbit is a validated model for vaginal irritancy testing, little is
known about the rabbit female genital tract as an inductive site for
mucosal and systemic immunity.
5. Conclusions
This study has described the design and development of a
mucoadhesive, syringeable, rheologically structured gel system
for site-retentive application of an HIV vaccine candidate to the
vagina. The mechanical and mucoadhesive properties, release pro-
ﬁle of CN54gp140 and subsequent elicitation of speciﬁc immune
responses indicate that the RSV gel may have an advantageous
role promoting persistent/intimate exposure of CN54gp140 to the
mucosal-associated lymphoid tissue of the female genital, thus
augmenting and prolonging CN54gp140-speciﬁc local immune
responses in comparison to more conventional gel formulations.
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